A Phase I, Multicenter, Open-Label, Dose-Escalation Study of Oral LDE225 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 23 Sep 2016
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer; Medulloblastoma; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 23 Sep 2016 Results of pooled analysis of this and other three studies on patients and four on volunteers published in the European Journal of Clinical Pharmacology (2016).
- 20 Apr 2016 Results of PK analysis of BOLT study and pooled analysis of other three studies including this published in the Journal of Clinical Pharmacology
- 14 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.